Close Menu

NEW YORK (GenomeWeb News) – UK-based molecular diagnostics startup Enigma Diagnostics has inked an agreement with GlaxoSmithKline to develop and market point-of-care influenza tests that will run on Enigma's PCR-based platform, Enigma ML.

Under terms of the worldwide development and supply deal, GSK will make a small, undisclosed equity investment in Enigma. It also will provide Enigma with an upfront payment, research and development funding, milestone payments, and profit sharing on sales of products developed under the collaboration.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

Mar
09
Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
16
Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.